OXOLAMINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H19N3O
Molecular Weight	245.3202
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2

InChI

InChIKey=IDCHQQSVJAAUQQ-UHFFFAOYSA-N

InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C14H19N3O
Molecular Weight	245.3202
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Oxolamine under brand names Symphocal, Perebron is used in some countries as a cough suppressant for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis, pertussis. Oxolamine possesses anti-inflammatory activity, which causes a reduction in the irritation of the nervous receptors of the respiratory tract.

Approval Year

Conditions

Conditions

Condition	Modality	Highest Phase	Product
Cough 106	Palliative	Approved 8,429	Perebron
Tracheitis 3	Palliative	Approved 8,429	Perebron
Bronchitis 51	Palliative	Approved 8,429	Perebron
Pertussis 3	Palliative	Approved 8,429	Perebron

PubMed

Show entries

Title	Date	PubMed
Effect of oxolamine on cough sensitivity in COPD patients.	2002 Jan	11863211
Effect of oxolamine on anticoagulant effect of warfarin.	2006 Jan 15	16390929
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.	2007 Apr	17295362

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

In general, 15-25 mg per kilogram per day should be given by dividing four equal doses. In children over 2 years: 1-2 ml of 5 ml Adults: 2 ml of 5 ml 4 times daily 4 hours a day, after an equal amount of water.

Route of Administration: Oral

In Vitro Use Guide

Unknown